Abstract: The present invention provides a therapeutic agent or prophylactic agent for an ophthalmic disease caused by ocular angiogenesis, which contains a morpholine compound represented by the formula (1) wherein ring A is aryl optionally having substituent(s) and the like; ring B is arylene optionally having substituent(s) and the like; m=0-2; n=1-5; X is a bond and the like; Y is a bond and the like; and Z is a hydrogen atom and the like, or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: The present invention provides a therapeutic agent or prophylactic agent for an ophthalmic disease caused by ocular angiogenesis, which contains a morpholine compound represented by the formula (1) wherein ring A is aryl optionally having substituent(s) and the like; ring B is arylene optionally having substituent(s) and the like; m=0-2; n=1-5; X is a bond and the like; Y is a bond and the like; and Z is a hydrogen atom and the like, or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: A compound represented by the formula (1) wherein ring A is aryl optionally having substituent(s) and the like; ring B is arylene optionally having substituent(s) and the like; m=0-2; n=1-5; X is a bond and the like; Y is a bond and the like; and Z is hydrogen atom and the like or a pharmaceutically acceptable salt thereof, and a hydrate or solvate thereof have affinity for CCR3, and can be pharmaceutical products for the treatment and/or prophylaxis of immune or inflammatory diseases.

Abstract: A seat apparatus includes a seat back capable of being used as a table at a surface thereof, a seat back driving device moving the seat back between a seating position and a table position, a controlling portion controlling the seat back driving device, and the controlling portion including an operating portion at which the user executes a certain operation, wherein, when the user executes the certain operation, the controlling portion controls the seat back to move in a first direction that is opposite to a second direction to which the seat back is moved most recently.

Abstract: A seat apparatus includes a seat cushion on which an operator is seated, a seatback for supporting the operator seated on the seat cushion, a seat drive device changing a position of the seat cushion and the seatback between a seating position and a storage position by operating the seat cushion and the seatback, and a control unit for controlling the seat drive device, the control unit controlling the seat drive device in a way that an operation starting time of the seat cushion does not coincide with an operation starting time of the seatback and an operating time of the seat cushion overlaps temporally an operating time of the seatback when the seat cushion and the seatback are moved between the seating position and the storage position such that an interference of the seat cushion and the seatback is restricted.

Abstract: A seat apparatus includes a seat cushion on which an operator is seated, a seatback supporting the operator seated on the seat cushion, the seatback being configured to incline forward to reduce an angle of the seatback relative to the seat cushion and to incline rearward to increase the angle of the seatback relative to the seat cushion, a seatback drive device inclining the seatback forward and rearward relative to the seat cushion, a seatback operating switch provided at a position where is reached by the operator seated on the seat cushion, the seatback operating switch operating the seatback driving device in response to an operation of the switch, and an excessive load restricting device restricting an excessive load applied to the operator seated on the seat cushion by limiting a forward inclination of the seatback when the seatback operating switch is operated so as to incline the seatback forward.

Abstract: A compound represented by the formula (1) wherein ring A is aryl optionally having substituent(s) and the like; ring B is arylene optionally having substituent(s) and the like; m=0-2; n=1-5; X is a bond and the like; Y is a bond and the like; and Z is hydrogen atom and the like or a pharmaceutically acceptable salt thereof, and a hydrate or solvate thereof have affinity for CCR3, and can be pharmaceutical products for the treatment and/or prophylaxis of immune or inflammatory diseases.

Abstract: A seat apparatus includes a seat back capable of being used as a table at a surface thereof, a seat back driving device moving the seat back between a seating position and a table position, a controlling portion controlling the seat back driving device, and the controlling portion including an operating portion at which the user executes a certain operation, wherein, when the user executes the certain operation, the controlling portion controls the seat back to move in a first direction that is opposite to a second direction to which the seat back is moved most recently.

Abstract: A seat apparatus includes a seat cushion on which an operator is seated, a seatback supporting the operator seated on the seat cushion, the seatback being configured to incline forward to reduce an angle of the seatback relative to the seat cushion and to incline rearward to increase the angle of the seatback relative to the seat cushion, a seatback drive device inclining the seatback forward and rearward relative to the seat cushion, a seatback operating switch provided at a position where is reached by the operator seated on the seat cushion, the seatback operating switch operating the seatback driving device in response to an operation of the switch, and an excessive load restricting device restricting an excessive load applied to the operator seated on the seat cushion by limiting a forward inclination of the seatback when the seatback operating switch is operated so as to incline the seatback forward.

Abstract: A seat apparatus includes a seat cushion on which an operator is seated, a seatback for supporting the operator seated on the seat cushion, a seat drive device changing a position of the seat cushion and the seatback between a seating position and a storage position by operating the seat cushion and the seatback, and a control unit for controlling the seat drive device, the control unit controlling the seat drive device in a way that an operation starting time of the seat cushion does not coincide with an operation starting time of the seatback and an operating time of the seat cushion overlaps temporally an operating time of the seatback when the seat cushion and the seatback are moved between the seating position and the storage position such that an interference of the seat cushion and the seatback is restricted.

Abstract: The object of the present invention is to provide a compound having a treatment effect based on a chemokine inhibitory activity, which is satisfactory as a pharmaceutical product for oral administration. The present inventors have found that the following benzylpiperidine derivative (the formula (1)) has a chemokine inhibitory activity. Further intensive studies have resulted in successful enhancement of the chemokine inhibitory activity and stability in blood of the present compound, as well as the completion of the present invention. wherein each symbol is as defined in the specification.

Abstract: The object of the present invention is to provide a compound having a treatment effect based on a chemokine inhibitory activity, which is satisfactory as a pharmaceutical product for oral administration.